[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598085":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":55,"centralContacts":59,"locations":66,"responsibleParty":105,"collaborators":107,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":64,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":138,"whyStopped":64,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,17,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Mild mitral regurgitation","EXPERIMENTAL","Patient suffuring from mild mitral regurgitation (n=30)",[13,14,15,16],"Diagnostic Test: Standard echocardiography","Diagnostic Test: 2D phase-contrast magnetic resonance imaging","Diagnostic Test: 4D flow magnetic resonance imaging","Diagnostic Test: Cardiac ultrafast ultrasound imaging",{"label":18,"type":10,"description":19,"interventionNames":20},"Moderate mitral regurgitation","Patient suffuring from moderate mitral regurgitation (n=30)",[13,14,15,16],{"label":22,"type":10,"description":23,"interventionNames":24},"Severe mitral regurgitation","Patient suffuring from severe mitral regurgitation (n=100)",[13,14,15,16],[26,35,43,49],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DIAGNOSTIC_TEST","Standard echocardiography","Routine ultrasound examination with standardized recordings for the study, incorporating volumetric assessment techniques",[9,18,22],[32,33,34],"Cardiac echography","TTE","Heart ultrasounds",{"type":27,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"2D phase-contrast magnetic resonance imaging","A cardiac MRI will be performed on a 1.5 Tesla system, including a biventricular function study with a series of short-axis slices, three long-axis slices, a 2D phase-contrast acquisition orthogonal to the aortic root. Additionally, standard T1 mapping sequences will be acquired on three short-axis slices, 15 minutes after the injection of 0.2 mmol\u002Fkg of body weight of gadolinium, for myocardial and blood T1 measurements.",[9,18,22],[40,41,42],"2D MRI","Cardiac magnetic resonance imaging","CMR",{"type":27,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"4D flow magnetic resonance imaging","A sagittal 4D flow acquisition lasting between 6 and 10 minutes of free breathing to cover all four cardiac chambers is added to the 2D acquisition.",[9,18,22],[48],"4D MRI",{"type":27,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"Cardiac ultrafast ultrasound imaging","Ultrafast sequences are added to the standard echocardiography acquisition.",[9,18,22],[54],"ultrafast echocardiography",[56],{"name":57,"affiliation":5,"role":58},"Gilles Soulat","PRINCIPAL_INVESTIGATOR",[60],{"name":61,"role":62,"phone":63,"phoneExt":64,"email":65},"Maxime Brussieux","CONTACT","+33",null,"maxime.brussieux@aphp.fr",[67,83,96],{"facility":68,"status":64,"city":69,"state":64,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Groupe hospitalier Paris Saint-Joseph - hôpital Marie-Lannelongue","Le Plessis-Robinson","92350","France","FR",{"type":74,"coordinates":75},"Point",[76,77],2.27078,48.78889,{"lat":77,"lon":76},[80],{"name":81,"role":62,"phone":64,"phoneExt":64,"email":82},"Arshid Azarine","aazarine@ghpsj.fr",{"facility":84,"status":64,"city":85,"state":64,"zip":86,"country":71,"countryCode":72,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"AP-HP - hôpital Saint-Antoine","Paris","75012",{"type":74,"coordinates":88},[89,90],2.3488,48.85341,{"lat":90,"lon":89},[93],{"name":94,"role":62,"phone":64,"phoneExt":64,"email":95},"Ariel Cohen","ariel.cohen@aphp.fr",{"facility":97,"status":64,"city":85,"state":64,"zip":98,"country":71,"countryCode":72,"cosmosGeoPoint":99,"geoPoint":101,"contacts":102},"AP-HP - hôpital européen Georges-Pompidou,","75015",{"type":74,"coordinates":100},[89,90],{"lat":90,"lon":89},[103],{"name":57,"role":62,"phone":64,"phoneExt":64,"email":104},"gilles.soulat@aphp.fr",{"type":106,"investigatorFullName":64,"investigatorTitle":64,"investigatorAffiliation":64,"oldNameTitle":64,"oldOrganization":64},"SPONSOR",[108,111],{"name":109,"class":110},"Ministry of Health, France","OTHER_GOV",{"name":112,"class":113},"GIRCI IDF","UNKNOWN","100598085","quantification-of-mitral-regurgitation-using-4d-mri-flow--comparison-with-2d-mri-flow-and-echocardiography-using-the-evolution-of-left-ventricular-remodeling-as-a-reference-100598085",false,"NCT07066904","Quantification of Mitral Regurgitation Using 4D MRI Flow : Comparison With 2D MRI Flow and Echocardiography Using the Evolution of Left Ventricular Remodeling as a Reference","FLAME","Inclusion Criteria: Subjects\n\n* from 18 to 85 years old\n* having signed a consent form to participate in the study\n* suffering from mild, moderate or severe mitral regurgitation based on an ultrasound graduation\n* able to undergo echocardiography and IRM within 7 days after recruitment and then at 6 months\n\nExclusion Criteria: Subjects\n\n* suffering from aortic regurgitation or stenosis or mitral stenosis associated with more than moderate MR, intracardiac shunting or hypertrophic cardiomyopathy\n* suffering from secondary MR\n* having a contraindication to gadolinium-based contrast agent\n* having a pacemaker, defibrillator or any other contraindication to MRI\n* suffering from renal disease with an eGFR CKD-EPI \\\u003C 30 ml\u002Fmin\n* pregnant or breastfeeding\n* under legal protection\n\nEnrolled subjects:\n\n* with an incomplete or suboptimal ultrasound or MRI examination\n* who have not attended to the 6-month follow-up visit\n* with an intercurrent medical event\n\nwill be excluded.","ALL","18 Years","85 Years",{"count":125,"type":126},160,"ESTIMATED","INTERVENTIONAL",[129],"NA","The goal of this study is to evaluate whether 4D MRI provides a better assessment of mitral regurgitation quantification and associated ventricular remodeling than standard imaging techniques: echocardiography and 2D MRI, in patients suffuring from mitral regurgitation. 4D MRI demonstrated its superiority to 2D MRI in some other valve diseases but remains not widely used, due to a lack of evidence. The main question our study aims to answer is:\n\n• Is mitral regurgitant volume measured on 4D MRI more strongly related to remodeling progression (after correction of regurgitation or not) than regurgitant volume measured on 2D MRI and echocardiography?\n\nParticipants will undergo 4D MRI, 2D MRI and echocardiography twice at six-month intervals.",[132],"Mitral Regurgitation (MR)",[134,48,135,136,137,54],"Mitral regurgitation","4D-flow MRI","cardiovascular magnetic resonance","Ultrafast ultrasound imaging","NOT_YET_RECRUITING","2025-07-04",{"date":141,"type":142},"2025-07-15","ACTUAL",{"date":144,"type":126},"2025-10-01",{"date":146,"type":126},"2028-04-30",{"name":5,"class":6},3]